Global Information
회사소개 | 문의

녹내장 치료제 리포트(2018년) : 세계 시장 분석(2017-2023년)

2018 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2017 to 2023

리서치사 Market Scope, LLC
발행일 2018년 06월 상품 코드 644810
페이지 정보 영문
가격
US $ 6,800 ₩ 7,692,000 PDF by Email (Single User License)
US $ 10,200 ₩ 11,539,000 PDF by Email (Enterprise License)


녹내장 치료제 리포트(2018년) : 세계 시장 분석(2017-2023년) 2018 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2017 to 2023
발행일 : 2018년 06월 페이지 정보 : 영문

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

세계 녹내장 치료제 시장의 2018년 규모는 제조업체 매출 기준 48억 달러에 이르렀습니다.

세계의 녹내장 치료제(Glaucoma Pharmaceuticals) 시장에 대해 조사했으며, 녹내장 개요, 유병률과 진단 사례, 의료기관, 진단법, 치료법, 시판약, 처방약 개발 파이프라인, 외과 수술에서 사용되는 보조제, 주요 기업 개요 등의 정보를 정리했습니다.

1. 서론

2. 주요 요약

3. 녹내장에 대해

  • 개방각 녹내장(OAG)
    • 정상안압 녹내장
    • 낙설 녹내장
  • 폐색우각 녹내장(ACG)
  • 연발성 녹내장
    • 색소성 녹내장
    • 신생혈관 녹내장
    • 포도막염 녹내장
    • 외상성 녹내장
    • 스테로이드 녹내장
    • 수정체 녹내장
    • 홍채각막내피 증후군(ICE 증후군)
    • 선천성 녹내장
  • 고안압증(OHT)
  • 녹내장의 유전적 특징

4. 녹내장 유병률

  • 녹내장 유병률 조사 개요
    • 세계의 유병률 : 질환 종류별
    • 세계의 녹내장 분포를 형성하는 요인
    • POAG의 진단
    • PACG의 진단
  • 미국
  • 서유럽
  • 일본
  • 기타 부유국
  • 중국
  • 인도
  • 라틴아메리카
  • 기타(ROW)
  • 녹내장 인구 증가 요약

5. 녹내장 의료기관

  • 의료기관, 진단, 치료 개요
  • 미국
  • 서유럽
  • 일본
  • 기타 부유국
  • 중국
  • 인도
  • 라틴아메리카
  • 기타(ROW)

6. 녹내장 진단

  • 안압측정
  • 각막두께측정
  • 시야 검사 및 시력 검사
  • 검안경 검사
  • 안저 촬영
  • 광간섭단층촬영(OCT)
  • 공초점 주사형 레이저 검안경(SLO) 등

7. 녹내장 치료

  • 치료법
  • 처방약
  • 개방각 녹내장(OAG)의 치료
  • 고안압 환자의 IOP 치료
  • 박리/거짓비늘(Pseudoexfoliation) 치료
  • 녹내장(XFG/PEG)
  • 폐색각 녹내장(ACG) 치료
  • 현재 치료제의 한계
  • 녹내장 전문의에 대한 소개
  • 레이저와 외과수술 등

8. 녹내장 관리 과제

  • IOP의 주요 역할
  • IOP 및 녹내장에 관한 경쟁 이론
  • 녹내장 치료 옵션 증가
  • 안과의가 최선의 POAG 치료 옵션을 결정하는 방법
  • POAG 병기 및 전형적인 치료 방법

9. 시장의 녹내장 치료제

  • Rho 키나아제 억제제
  • 프로스타글란딘 유사체 및 프로스타마이드
  • 합성 도코사노이드
  • 베타 차단제
  • 알파 작용제
  • 탄산탈수효소 억제제
  • 콜린 작용제 등

10. 녹내장 치료제 시장 예측

  • 부유국의 전망
  • 신흥 시장의 경제 전환
  • 녹내장 수술의 역할 변화
  • 세계의 녹내장 치료제 시장
  • 세계 시장 : 치료제 클래스별
  • 세계 시장 : 경쟁사별
  • 세계의 녹내장 처방약 시장 예측 등

11. 녹내장 치료제 개발 파이프라인

  • 프로스타글란딘 유사체
  • Rho 키나아제 저해약
  • 아데노신 수용체 작용제 및 길항제
  • EP 수용체 작용제
  • 신경세포보호 및 신경재생 등

12. 녹내장 외과수술에 사용되는 보조약

  • 오프라벨에 사용되는 화합물
  • Mobius Therapeutics Mitosol
  • Altacor/Esperante ALT 401(Tranilast)

13. 기업 개요

  • Aerie Pharmaceuticals
  • Akorn
  • Allergan, PLC
  • Amorphex Therapeutics LLC
  • Bausch + Lomb
  • BioLight Life Sciences Ltd.
  • Eyenovia, Inc.
  • Glaukos Corporation
  • Kowa Company, Ltd.
  • Laboratoires Thea
  • Laboratorios Sophia, SA de CV
  • Mati Therapeutics, Inc.
  • Mobius Therapeutics LLC
  • Mundipharma
  • Neurotech Pharmaceuticals, Inc.
  • Nicox
  • Novartis Innovative Medicines
  • Ocular Therapeutix
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer
  • pH Pharma
  • Quark Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Sylentis
  • 기타 기업
  • 녹내장 제네릭 의약품 기업
LSH 18.11.21

Market Scope's “2018 Glaucoma Pharmaceuticals Report” provides in-depth coverage of commercialized and investigational glaucoma medications in the market.

Four disease categories are analyzed in this report:

  • Primary open-angle glaucoma (POAG), primary angle-closure glaucoma (PACG), other secondary OAG and ACG, and ocular hypertension (OHT).

Each market segment includes:

  • An analysis of market competitors and five-year forecasts for market performance.

Also included in this report:

  • Overview of glaucoma;
  • Prevalence of glaucoma and diagnosed cases;
  • Glaucoma care providers;
  • Diagnosing glaucoma;
  • Treating glaucoma;
  • Glaucoma medications in the marketplace;
  • Development pipeline for glaucoma Rx;
  • Adjunctive drugs used in glaucoma surgery;
  • 25 company profiles;
  • 54 color tables and 33 color figures.

Our report on the glaucoma pharmaceuticals market, now in its fifth edition, is a leading industry source for accurate and relevant information on all aspects of the glaucoma pharmaceuticals market. The report analyses 61 marketed medications and differences in their popularity around the world, 16 pipeline agents in development, 22 discontinued drug candidates, 10 clinical stage alternative drug delivery platforms, 10 preclinical alternative drug delivery platform programs, and another nine university-based drug delivery research programs. It also includes new market forecasts based on updated information from use surveys and price surveys.

Our Process:

Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective ophthalmic experience and each data point is driven by a combination of sources, including the following:

  • Our proprietary global disease population and demographic models
  • Twenty years and counting of ophthalmologist survey data
  • Analysis of company published financial reports
  • Focused coverage of ophthalmic scientific research, business news, and other activities
  • Attendance and participation in major, worldwide ophthalmic meetings
  • Interviews and long-standing relationships with company executives and practicing ophthalmologists

This report includes market data for 2017, and we forecast market performance through 2023.

Table of Contents

INTRODUCTION

  • Scope of Report
  • Methodology
  • About the Author
  • The Report at a Glance

EXECUTIVE SUMMARY

  • Glaucoma and its Prevalence
  • The Global Market
  • Current Market Competitors
  • Factors Shaping the Marketplace

ABOUT GLAUCOMA

  • Open-Angle Glaucoma (OAG)
    • Normal-Tension Glaucoma as a Subset of OAG
    • Exfoliation Glaucoma (XFG) as a Subset of OAG
  • Angle-Closure Glaucoma (ACG)
    • Secondary Glaucomas
    • Pigmentary Glaucoma
    • Neovascular Glaucoma
    • Uveitic Glaucoma
    • Trauma-Related Glaucoma
    • Steroid-Induced Glaucoma
    • Lens-Induced Glaucoma
    • Iridocorneal Endothelial Syndrome
    • Congenital Glaucoma
  • Ocular Hypertension (OHT)
  • Genetics of Glaucoma

PREVALENCE OF GLAUCOMA

  • Overview of Glaucoma Prevalence
    • Global Prevalence by Disease Type
    • Factors Shaping Worldwide Distribution of Glaucoma
    • Diagnosed POAG
    • Diagnosed PACG
  • United States
  • Western Europe
  • Japan
  • Other Wealthy Nations
  • China
  • India
  • Latin America
  • Rest of World
  • Global Glaucoma Population Growth Summary

GLAUCOMA CARE PROVIDERS

  • Overview of Providers, Diagnosis, Treatment
    • Care Providers and Diagnostic Facilities
  • US Providers
    • US Ophthalmologists and Glaucoma Specialists
    • Profile of the US Ophthalmologist
    • Profile of the US Optometrist
  • Western Europe's Providers
    • Ophthalmology and Health Care Systems
    • Optometry
  • Japan's Providers
    • Ophthalmology and the Health Care System
    • Optometry
  • Other Wealthy Nations' Providers
    • Ophthalmology and Health Care Systems
    • Optometry
  • China's Providers
    • Ophthalmology and the Health Care System
    • Optometry
  • India's Providers
    • Ophthalmology and the Health Care System
    • Optometry
  • Latin America's Providers
    • Ophthalmology and Health Care Systems
    • Optometry
    • Select Country Snapshots
  • Rest of World's Providers
    • Ophthalmologist and Health Care Systems
    • Optometry
  • Glaucoma Organizations and Foundations

DIAGNOSING GLAUCOMA

  • Tonometry
  • Pachymetry
  • Perimetry or Visual Field Testing
  • Ophthalmoscopy
  • Fundus Photography
  • Optical Coherence Tomography
  • Confocal Scanning Laser Ophthalmoscopy
  • Scanning Laser Polarimetry
  • Glaucoma Scope Examination
  • Slit Lamp Biomicroscopy
  • Gonioscopy with Contact Lens
  • Ultrasound Biomicroscopy
  • Biomarkers
  • Use Artificial Intelligence
  • Diagnosed Disease Rates
    • Growth in Glaucoma's Diagnosis

TREATING GLAUCOMA

  • Treatment Modalities
  • Rx Medications
    • Treating Open-Angle Glaucoma
    • Treating IOP in Ocular Hypertension Patients
    • Treating Exfoliation/Pseudoexfoliation Glaucoma (XFG/PEG)
    • Treating Angle-Closure Glaucoma
    • Limitations of Current Medications
    • Referral to Glaucoma Specialists
  • Laser and Surgery
    • Laser Procedures
    • Traditional Surgical Treatment
    • Newer Surgical Approaches
  • Traditional Medicine and Alternative Therapies
    • China
    • India
    • Other Alternative Medicine
    • Marijuana

THE CHALLENGES OF MANAGING GLAUCOMA

  • The Role of IOP
  • A Competing Theory Regarding IOP and Glaucoma
  • Monitoring IOP
  • Growing Glaucoma Treatment Options
  • How Ophthalmologists Determine the Best POAG Treatment Option
  • POAG Stages and Typical Treatment Approaches

GLAUCOMA MEDICATIONS IN THE MARKETPLACE

  • Cholinergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Alpha Agonists
    • Selective Alpha2 Adrenergic Agonists
    • Nonselective Alpha Adrenergic Agonists
  • Beta Blockers
  • Synthetic Docosanoids
  • Prostaglandin Analogs and Prostamides
  • Nitric-Oxide Donating Prostaglandin Analogs
  • Rho Kinase Inhibitor
  • Fixed Combination Medications
  • Comparative IOP Reduction: Brands and MOAs
  • The Market Mix: Original Medications and Generics
    • Branded Proprietary IOP-lowering Medications
    • Generic IOP-lowering Medications
    • Branded Generics

FORECAST FOR THE GLAUCOMA PHARMA MARKET

  • Prospects in Wealthy Nations
  • Economic Shifts in Emerging Markets
  • Changing Role of Glaucoma Procedures
  • Global Market for Glaucoma Medications
    • The Global Market by Medication Class
    • The Global Market by Competitor
  • Forecast for the Global Glaucoma Rx Market
  • US Market for Glaucoma Medications
  • Western Europe's Market for Glaucoma Medications
  • Japan's Market for Glaucoma Medications
  • OWN's Market for Glaucoma Medications
  • China's Market for Glaucoma Medications
  • India's Market for Glaucoma Medications
  • Latin America's Market for Glaucoma Medications
  • ROW's Market for Glaucoma Medications

DEVELOPMENT PIPELINE FOR GLAUCOMA PHARMA

  • Prostaglandin Analogs
    • Ono Pharmaceutical/Santen Sepetaprost
    • Santen/Novagali Pharma: Catioprost
    • Novaliq GmbH: Water and Preservvative Free Latanoprost
    • Nitric Oxide-Related Compounds
    • Nicox: NCX 470 and NCX 667
    • Ironwood Pharmaceuticals: IWP-953
    • Chang Gung University: Antioxidant Hydrogels
  • Rho-kinase Inhibition
    • pH Pharma PHP-201 (formerly Amakem NV:AMA0076)
    • Discontinued Rho-Kinase Inhibitors
  • Adenosine Receptor Agonists and Antagonists
    • Acorn Biomedical: ACN-1052
    • Discontinued Adenosine Receptor Agonists
    • Inotek Pharmaceuticals: Trabodenoson (INO-8875)
  • Angiopoeitin and Tie2
    • Aerpio Pharmaceuticals AKB-9778
    • Q BioMed Man-01
  • EP Receptor Agonists
    • Santen: DE-117 (omidenepag isopropyl)
    • Discontinued EP Receptor Agonists
  • Additional IOP-lowering Compounds
    • Sylentis: Bamosiran (SYL-040012)
  • Neuroprotection and Neuroregeneration
    • Quark Pharmaceuticals: QPI-1007
    • Other Neuroprotective Compounds
    • Discontinued Candidates
  • Fixed Combinations of Agents
    • Aerie Pharmaceuticals: Roclatan
    • Laboratoires Théa: T2347
  • New Drug Delivery Technologies
    • Clinical Stage Programs
    • Preclinical Programs
  • Gene Therapies
    • Discontinued Efforts
  • Stem Cell Therapies
  • Review of Investigational Technologies

ADJUNCTIVE DRUGS USED IN GLAUCOMA SURGERY

  • Compounds Used Off Label
  • Mobius Therapeutics' Mitosol
  • Altacor/Esperante's ALT 401 (Tranilast)

COMPANY PROFILES

  • Aerie Pharmaceuticals
  • Akorn
  • Allergan, PLC
  • Amorphex Therapeutics LLC
  • Bausch + Lomb
  • BioLight Life Sciences Ltd.
  • Eyenovia, Inc.
  • Glaukos Corporation
  • Kowa Company, Ltd.
  • Laboratoires Théa
  • Laboratorios Sophia, SA de CV
  • Mati Therapeutics, Inc.
  • Mobius Therapeutics LLC
  • Mundipharma
  • Neurotech Pharmaceuticals, Inc.
  • Nicox
  • Novartis Innovative Medicines
  • Ocular Therapeutix
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer
  • pH Pharma
  • Quark Pharmaceuticals
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries, Inc.
  • Sylentis
  • Additional Companies in this Report
  • Companies Marketing Generic Glaucoma Medications

TABLE OF TABLES

TABLE OF FIGURES

Back to Top
전화 문의
이용안내
 
BCC Research